CORPORATE MEDIA RELEASE
NORGINE OPENS ITS NEW CORPORATE HEADQUARTERS IN AMSTERDAM
AMSTERDAM. The Netherlands, Wednesday 24 January 2018, 08:00 AM CET. Norgine B.V. today announced that it has opened its new headquarters in the heart of Amsterdam’s business district, at Cross Towers, Antonio Vivaldistraat 150, 1083 HP Amsterdam, Netherlands.
Peter Stein, CEO of Norgine said: “Our investment in our new headquarters, one of Norgine’s 14 sites in Europe, is representative of our strong belief that there is no better place to expand our European business than from a strong and continued base in the Netherlands.”
He added: “We are confident that our investment in Amsterdam will help us to ensure that we can continue to attract and retain talent from across Europe as well as facilitate our agile and flexible approach to partnerships.”
The office was opened by Frank Nooteboom, General Manager, Norgine Netherlands and guest Mr. Schouw, General Manager of the Dutch Association for Innovative Medicines.
Here’s what Norgine’s new headquarters look like:
Norgine offices are located in the EY building at Cross Towers
Peter Stein, CEO Norgine
Peter Stein is the Chairman and Chief Executive Officer and principal shareholder of the Norgine Group. Norgine B.V., the primary subsidiary of the group, is a European specialist pharmaceutical company with operations throughout Europe, Australia and New Zealand. Peter also serves as the Chief Executive of Norgine Ventures, which provides financing solutions to innovative healthcare companies.
Prior to joining Norgine in 1987, Peter was a co-founder and Vice President of Invitron Corporation, a contract biomanufacturer formed as a spin-off from the Monsanto Company. He started his pharmaceutical career with Centocor.
Peter holds BA and MA degrees in Chemistry from Harvard University and an MBA from Stanford University.
In addition to his role at Norgine, Peter is a non-executive Director of Agendia N.V., a molecular diagnostics company based in Amsterdam.
Gerard Schouw, General Manager of the Dutch Association for Innovative Medicines
Gerard Schouw (52) became General Manager of the Dutch Association Innovative Medicines in August 2015. The Association is a branch organisation that represents the interests of 44 pharmaceutical companies. Schouw has a comprehensive track record in Dutch politics. Between 2010 and 2015 he represented political party D66 in the Dutch parliament. From 2003 until 2010 he was a member of the Dutch Senate. In 1996 Schouw obtained a PhD from Leiden University on the Management styles of alderman.
Frank Nooteboom, General Manager Norgine Netherlands
Frank Nooteboom joined Norgine in 1988 as a sales representative. During his time at Norgine, Frank has held a number of positions in the Netherlands and in Norgine’s European offices. As General Manager Netherlands, Frank leads the Dutch operations and also holds some directorships within the group.
Notes to Editors:
About Norgine
Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2016, Norgine’s total revenue was EUR 368 million. Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply.
Norgine specialises in gastroenterology, hepatology, cancer and supportive care.
Norgine is headquartered in the Netherlands. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites in Hengoed, Wales and Dreux, France.
For more information, please visit www.norgine.com
In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.
NORGINE and the sail logo are trademarks of the Norgine group of companies.
Media Contacts:
Isabelle Jouin, T: +44 (0)1895 453643
Follow us @norgine
Norgines webbplatser
Kontakta oss